vimarsana.com

Page 18 - முன்னேற்றங்கள் பார்மா அறிவியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

HDFC Bank | Aditya Puri: Former HDFC Bank MD Aditya Puri joins global pharma major Strides Group as advisor

Former HDFC Bank MD Aditya Puri joins biopharma company Strides as advisor

Former HDFC Bank MD Aditya Puri joins biopharma company Strides as advisor Aditya Puri said that he was looking forward to working with Kumar and building world-class institutions to produce high-quality affordable biotherapeutics and CDMO services BusinessToday.In | January 8, 2021 | Updated 13:51 IST Aditya Puri joins biopharma group as advisor Former HDFC Bank Managing Director Aditya Puri has joined Strides Group as Advisor and Stelis Biopharma Bengaluru as Director. Strides Pharma Science Limited is pleased to announce that eminent corporate doyen Aditya Puri joins the Strides Group as an Advisor and also will be a Director of its associate Company, Stelis Biopharma, announced the company.

एचडीएफसी बैंक के पूर्व एमडी आदित्य पुरी स्ट्राइड्स समूह से जुड़े

एचडीएफसी बैंक के पूर्व एमडी आदित्य पुरी स्ट्राइड्स समूह से जुड़े
business-standard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from business-standard.com Daily Mail and Mail on Sunday newspapers.

एचडीएफसी बैंक के पूर्व एमडी आदित्य पुरी स्ट्राइड्स समूह से जुड़े - former hdfc bank md aditya puri joins strides group

एचडीएफसी बैंक के पूर्व एमडी आदित्य पुरी स्ट्राइड्स समूह से जुड़े - former hdfc bank md aditya puri joins strides group
indiatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatimes.com Daily Mail and Mail on Sunday newspapers.

Strides Pharma may get transferred to a clutch of investors as promoters plan to exit

Strides Pharma may get transferred to a clutch of investors as promoters plan to exit December 30, 2020 Company’s vaccine facility likely to go on stream in January Strides Pharma Science Limited, with no successors to take the company forward, is at crossroads as promoters are planning to exit. With their plan to exit the company, it is learnt that the company may get transferred to a clutch of investors. “The company is expected to be transferred to a clutch of investors as the promoters are looking to exit for personal reasons,” said a veteran pharma specialist, who did not want to be identified.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.